華林證券(002945.SZ):約4.8479億股首發限售股將解禁 股東深圳怡景承諾24個月內不減持
格隆匯1月19日丨華林證券(002945.SZ)公佈,公司首次公開發行前已發行股份此次解除限售日期為2020年1月21日,解除限售數量約4.8479億股,佔公司總股本的17.9552%。
持有此次解除限售股份的股東深圳市怡景食品飲料有限公司承諾:“自2020年1月17日(公司首發限售股上市流通之日)起,至2022年1月17日止,24個月內不減持其持有的公司股份。若未履行上述承諾,其減持所得收益全部歸公司所有。”經與深圳市怡景食品飲料有限公司確認,上述公司首發限售股上市流通之日以實際上市流通之日為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.